Novo Nordisk A/S Class B PEG Ratio

The latest PEG ratio for NONOF is -54.17. That is below the Healthcare sector average of 2.56. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, NONOF currently prints -54.17 for PEG ratio, while the sector average sits near 2.56. That is roughly 2216.2% below the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.

A PEG ratio of -54.17 for Novo Nordisk A/S Class B is not 'good' or 'bad' on its own. Compare it with the peer average (2.56) and with NONOF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting NONOF's PEG ratio (-54.17), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Novo Nordisk A/S Class B's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.